Literature DB >> 8124728

The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation.

J L Cleland1, M F Powell, S J Shire.   

Abstract

The biochemical literature has been surveyed to present an overview of the three most common protein degradation pathways: protein aggregation, deamidation, and oxidation. The mechanisms for each of these degradation routes are discussed with particular attention given to the effect of formulation conditions such as pH, ionic strength, temperature, and buffer composition. Strategies to reduce protein degradation are also discussed. These strategies are based on an understanding of the degradation mechanisms and the effect of changes in the storage conditions and formulation components on the degradation. The effects of each of the degradation routes on pharmaceutically relevant properties such as biological activity, metabolic half-life, and immunogenicity are summarized. Predicting a priori the alteration of pharmaceutical properties caused by the three degradation routes is difficult, and must be determined on a case-by-case basis for each protein. The difficulty in predicting the effect of degradation and analyzing the temperature dependence of reaction rates in proteins results in longer development times for protein formulations than for small molecule formulations. Although the use of accelerated stability to predict protein shelf life is difficult, conditions are discussed whereby the Arrhenius equation can be used to shorten formulation development time.

Mesh:

Substances:

Year:  1993        PMID: 8124728

Source DB:  PubMed          Journal:  Crit Rev Ther Drug Carrier Syst        ISSN: 0743-4863            Impact factor:   4.889


  103 in total

Review 1.  Protein instability in poly(lactic-co-glycolic acid) microparticles.

Authors:  M van de Weert; W E Hennink; W Jiskoot
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

2.  Rapid measurement of protein osmotic second virial coefficients by self-interaction chromatography.

Authors:  Peter M Tessier; Abraham M Lenhoff; Stanley I Sandler
Journal:  Biophys J       Date:  2002-03       Impact factor: 4.033

3.  Inverse relationship of protein concentration and aggregation.

Authors:  Michael J Treuheit; Andrew A Kosky; David N Brems
Journal:  Pharm Res       Date:  2002-04       Impact factor: 4.200

Review 4.  Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation.

Authors:  Eva Y Chi; Sampathkumar Krishnan; Theodore W Randolph; John F Carpenter
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

5.  Effect of polyols on the conformational stability and biological activity of a model protein lysozyme.

Authors:  Somnath Singh; Jagdish Singh
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

Review 6.  Structure-immunogenicity relationships of therapeutic proteins.

Authors:  Suzanne Hermeling; Daan J A Crommelin; Huub Schellekens; Wim Jiskoot
Journal:  Pharm Res       Date:  2004-06       Impact factor: 4.200

7.  Rational design of solution additives for the prevention of protein aggregation.

Authors:  Brian M Baynes; Bernhardt L Trout
Journal:  Biophys J       Date:  2004-09       Impact factor: 4.033

8.  Biotherapeutic formulation factors affecting metal leachables from stainless steel studied by design of experiments.

Authors:  Shuxia Zhou; Brad Evans; Christian Schöneich; Satish K Singh
Journal:  AAPS PharmSciTech       Date:  2012-01-13       Impact factor: 3.246

Review 9.  Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents.

Authors:  Denise M O'Hara; Valerie Theobald; Adrienne Clements Egan; Joel Usansky; Murli Krishna; Julie TerWee; Mauricio Maia; Frank P Spriggs; John Kenney; Afshin Safavi; Jeannine Keefe
Journal:  AAPS J       Date:  2012-03-14       Impact factor: 4.009

10.  Effect of N-1 and N-2 residues on peptide deamidation rate in solution and solid state.

Authors:  Bei Li; Richard L Schowen; Elizabeth M Topp; Ronald T Borchardt
Journal:  AAPS J       Date:  2006-03-20       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.